Determination and expression density of Fas (CD95) in Glioblastoma Multiforme samples from western Mexico patients

MG Guevara-Barraza; JR Domínguez-Rodríguez; NP Ramos-Huizar; Bravo-Cuéllar A

2014, Number 1

<< Back Next >>

Rev Med MD 2014; 5.6 (1)

Determination and expression density of Fas (CD95) in Glioblastoma Multiforme samples from western Mexico patients

Guevara-Barraza MG , Domínguez-Rodríguez JR , Ramos-Huizar NP , Bravo-Cuellar A

Full text

How to cite this article

Language: Spanish
References: 24
Page: 14-18
PDF size: 618.97 Kb.

ABSTRACT

Introduction. Glioblastoma Multiforme is the most common malignant tumor of the central nervous system. It accounts for 12 to 15% of the malignant intracranial neoplasms. Only 10% of the patients live more than two years after treatment is started. Fas (CD95) and its ligand targets one of the mechanisms involved in cellular apoptosis. Due to this fact we studied the presence of Fas in patients of a Specialized Unit at Centro Médico Nacional de Occidente del Instituto Mexicano del Seguro Social in Guadalajara, México
Material y Methods. This is a retrospective, descriptive study. A total of 20 formaldehyde-fixed and paraffin-embedded tissue block samples of glioblastoma multiforme represent 100% of the cases registered during two years. Fas was determined by immnohistochemistry. Its density and percentage of area expressed was determined by image analysis.
Results. 12 samples belonged to men and 8 belonged to women. The age ranged between 38 to 78 years, median 56.4 years. The tumors were located in the frontal lobe in 10 patients, temporal lobe in 9 patients and basal nuclei in 1 patient. 90% (n=18) of the samples were positive to Fas and they were more common among people between 50 to 59 years old, without localization pattern. Fas expression density ranged from 0 to 54.5, median 26.1+15.4%.
Discussion. We confirmed the expression of Fas in glioblastoma multiforme. The fact that Fas was absent in two patients and the wide percentage range of the area where it is expressed may limit its usefulness as a new therapeutic strategy.

REFERENCES

1.Omuro A, DeAngelis LM.: Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013; 310(17): 1842-1850.
2.Lefranc F, Kiss R. The sodium pump alpha1 subunit as a potential target to combat apoptosis-resistant glioblastomas. Neoplasia. 2008; 10(3): 198-206.
3.Ohgaki H, Kleihues P.: Genetic Pathways to Primary and Secondary Glioblastoma. Am J Pathol. 2007; 170(5): 1445–1453.
4.Lee KS, et al: Immunohistochemical Classification of Primary and Secondary Glioblastomas. Korean J Pathol. 2013; 47(6): 541-548.
5.- Kalkanis SN, et al. Raman spectroscopy to distinguish grey matter, necrosis, and glioblastoma multiforme in frozen tissue sections. J Neurooncol. 2014; 116(3): 477-485.
6.Rao SA, et al. A 16-gene signature distinguishes anaplastic astrocytoma from glioblastoma. PLoS One 2014;9(1): e85200
7.Kmiecik J, et al. Combining NK cells and mAb9.2.27 to combat NG2-dependent and anti-inflammatory signals in glioblastoma. Oncoimmunology. 2014; 3(1): e27185.
8.- Weil RJ. Incorporating molecular tools into earlystage clinical trials. Plos Med. 2008; 5(1): e21.
9.- Lefranc F, Kiss R. The Sodium Pump α1 Subunit as a Potential Target to Combat Apoptosis-Resistant Glioblastomas. Neoplasia. 2008; 10(3): 198–206.
10.-Elmore S.: Apoptosis: a review of programed cell death. Toxicol Pathol 2007; 35: 495-516.
11.Lerma–Díaz JM, et al. In vivo and in vitro sensitization of leukemic cells to adriamycin-induced apoptosis by pentoxifylline. Involvement of caspase cascades and IkB phosphorilation. Immunology Letters 2006; 103: 149-158.
12.Aguilar-Lemarroy A, et al. Apoptosis induction in Jurkat cells and sCD95 levels in women's sera are related with the risk of developing cervical cancer. BMC Cancer 2008; 11(8): 99-111.
13.Lavrik I, Golks A, Kramer PH: Death receptor signaling. J Cell Sci 2005, 118: 265-267.
14.- Fas Sc, et al. Death receptor signaling and its function in the immune system. Curr Dir Autoimmune 2006; 9:1-17.
15.-Nagata S. Fas ligand-induced apoptosis. Annu Rev Genet 1999; 33: 29-55.
16.- Tachibana O, et al. Expression of Fas/Apo-1 during the progression of Astrocytomas. Cancer Res. 1995; 55: 5528-5530.
17.Xia S, Rosen EM, Laterra J. Sensitization of glioma cells to Fas-dependent apoptosis by chemotherapyinduced oxidative stress. Cancer Res. 2005; 65(12): 5248-55.
18.Toprak AB, et al. Computer assited analysis of peroxidase stained endometrial tissue. Turk J Med Sci 2006; 36: 285-290.
19.Guevara-Donde JE. Incidencia de gliomas malignos en derechohabientes del IMSS residents en el estado de Veracruz, México. Arc. Neurocien 2004; 9: 80-84.
20.Tachibana O, et al. Preferential expression of Fas/APO1 (CD95) and apoptotic cell death in perinecrotic cells of glioblastoma multiforme. Acta Neuropathol 1996;92:431-434
21.- Sawhney M, et al. Age related changes in Fas (CD95) and Fas ligand gene expression and cytokine profiles in healthy Indians. Asian Pac J Allergy Immunol. 2006; 24(1): 47-56.
22.Töpfer K, et al. Tumor Evasion from T Cell Sur veillance. J Biomed Biotechnol.2011;Doi: 10.1155/2011/918471.
23.- Weller M, et al. Fas APO-1 gene transfer from human malignant glioma. Cancer Research 1955; 55(13): 2936-2944.
24.Frankel B, et al. Tumor Fas (APO-1/CD95) upregulation results in increased apoptosis and survival times for rats with intracranial malignant gliomas. Neurosurgery 2001; 49:168-175.